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Abstract: Psychosocial factors are important in the onset and1 
or exacerbation of psoriasis in 40%-80% of cases. Yet psoriasis 
has received little attention in the recent psychiatric literature. 
A subgroup of psoriatics appear to be “stress reactors” and 
these patients may have a better long-term prognosis. ldenti- 
fication of such patients early in the course of treatment and 
incorporation of specific psychosocial interventions in their 
overall treatment regimen may improve the course of illness. 
Psoriasis has also been associated with suicide and an increased 
prevalence of alcoholism. The disturbances in body image per- 
ception and the effect of psoriasis on interpersonal, social, and 
occupational functioning can further contribute to the overall 
morbidity, especially if psoriasis Frst occurs during a devel- 
opmentally critical period like adolescence. Certain biochemical 
and physiologic correlates of psoriasis of interest to the psy- 
chiatrist such as exacerbation of psoriasis with lithium therapy 
and increased cutaneous blood flow are discussed. Finally, some 
practical guidelines are provided for psychosocial interventions 
in psoriasis. 
Psoriasis is a chronic cutaneous condition with a 
l%-2% prevalence in the general population [l]. 
Both genetic and environmental factors are be- 
lieved to play an important role in the pathogenesis 
of this disorder [l]. Psoriasis is associated with an 
increased rate of proliferation of the epidermal 
cells; the characteristic lesions are deep red, thickly 
scaling plaques that may affect any region of the 
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skin. Psychosocial factors have been implicated by 
some as being important in the onset an&or exac- 
erbation of psoriasis in 40% [2-51 to 80% [6,7l of 
cases. Furthermore, psoriasis has been associated 
with suicide [8], and an increased prevalence of al- 
coholism in comparison with other chronic derma- 
tologic disorders [9], and a range of personality 
characteristics (Table 1) [3-7, 10-181. In the derma- 
tologic literature, psoriasis has been classified as a 
disorder where emotional and constitutional fac- 
tors “collaborate in different degrees” [20]. In the 
psychiatric literature, psoriasis is listed under psy- 
chosomatic disorders, or a disorder where psychol- 
ogic factors affect the physical condition (211. 
However, in spite of the fact that psoriasis may be 
significantly affected by psychosocial factors and be 
associated with potentially serious and life-threat- 
ening psychopathology, it has received very little 
attention in the recent psychiatric literature. 
Knowledge of the psychiatric and psychosocial 
concomitants of psoriasis is not only important for 
the consultation-liaison psychiatrist, but also for 
general psychiatrists, who will most likely encoun- 
ter patients with this common disorder in their 
practice. 
This paper critically evaluates the literature on 
the psychosocial aspects of psoriasis and reviews 
it under the following four major headings: 1) role 
of psychosocial “stress” in the onset or exacerba- 
tion of psoriasis, 2) association of psoriasis and psy- 
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Nature of Psoriatic Psychosocial 
Subjects Nature of Controls Measures Result 
Wittkower [3] 
1946 
86 Military patients No controls Clinical interviews a) No one personality 
type in psoriasis 
b) In 40% cases, 
emotional factors 
believed to be im- 
portant basis for 
psoriasis 
c) 16% were “psy- 
chiatrically ill” 
with a range of di- 






al. [4] 1959 
20 Inpatients No controls Maudsley Medical a) MMQ scores not 
Questionnaire significantly 
(MMQ) elevated 
b) In 40% cases psy- 
chologic factors as- 
sociated with 
onset of psoriasis, 
in 70% cases, they 
were associated 
with relapse. 
Goldsmith et 13 Inpatients Heterogenous a) Minnesota Multi- a) Increased scores in 
al. [lo] 1969 group of 13 der- phasic Personality psychasthenia and 
matologic Inventory (MMPI) hysteria subscales 
inpatients b) Maudsley Person- MMPI 
ality Inventory b) No significant dif- 
(MRI) ference between 
MPI scores 
Baughman et 
al. [ll] 1971 
200 Inpatients No controls Social Readjustment 
Rating Scale 
(Holmes and 
Rahe), used retro- 
spectively over 5 
years 
b) Cattels 16 PF test 
a) “Modest but signif- 
icant” correlation 
between stress and 
severity of pso- 
riasis at 0.28 
b) Personality profile 
scores within nor- 
mal range. 
Gilbert et al. 
[6] 1973 
63 48 inpatients 15 inpatients with a) Self-rating ques- 
15 outpatients other dermatoses tionnaire retro- 
spectively 
assessing the rela- 
tionship of anxiety 
to psoriasis 
b) California Person- 
ality Inventory 
a) 38% inpatients re- 
ported flare ups 
“always” associ- 
ated with “worry” 
42% reported flare 
ups “sometimes” 
associated with 
“worry” 26% con- 
(continued) 
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Nature of Psoriatic Psychosocial 
Subjects Nature of Controls Measures Result 
(CRI) sumed “tranquil- 
c) MMPI izer” to control 
psoriasis 20% con- 
sumed “moderate 
to heavy“ amounts 
of alcohol 
b) No significant ab- 
normalities on the 
CPI and MMPI. 
Jobling [ 121 
1976 
180 Members of the No controls Author’s own self- 84% reported “worst 
Psoriasis Associ- rating thing“ about hav- 
ation of the questionnaire ing psoriasis was 
United Kingdom difficulty encoun- 
tered in establish- 




Schaar [ 131 
1976177 
48 Outpatients “Psychosomatic pa- a) Amsterdam Bio- 
tients” with graphic Question- 
asthma, coronary naire (Wilde, 1963) 
artery disease, b) Social Anxiety 
dysmenorrhea Scale (Willens et 




132 Patients whose 130 patients with Patients asked if they 
psoriasis had re- upper respiratory had experienced a 
sponded well to infections and be- major upset or ill- 
treatment fol- nign or malignant ness just before 
lowed up for 3 skin tumors onset of rash 
years 
a) No difference be- 
tween psoriatics 





b) In both sexes so- 
cial anxiety scores 
did not differ from 
normals. 
a) 39% psoriatics ver- 
sus 10% controls 
recalled “specific 
stress” 1 month 
before onset of 
symptoms 
b) Relapse rate was 
lower when rash 
followed “stress.” 
Roenigk et al. 84 Inpatients and 
[14] 1978 outpatients 
No controls Authors’ own self- 
rating scale 
a) Psychosocial life of 
females more af- 
fected than males 
b) Authors attribute 
above to “females 
being more con- 





100 Patients who had No controls a) Thorough life 72% cases psoriasis 
been incarcer- history “stressogenic” 
ated during war 
(continued) 
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Nature of Psoriatic Psychosocial 
Subjects Nature of Controls Measures Result 
b) Author’s own “7 
point approach’ 
16% cases psoriasis 
“conflictogenic” 




7% no conslusion. 
Fava et al. [A 
1980 
20 Inpatients 20 inpatients with 
chronic uticaria 
20 inpatients with 
fungal infections 










a) 80% psoriatics, 
90% patients with 
chronic urticaria 
vs. 50% patients 
with fungal infec- 
tions reported at 
least 1 life event 6 
months prior to 
onset of symptoms 
b) Patients with pso- 
riasis and urticaria 
had higher anxi- 
ety, depression 
and inadequacy 
scores than pa- 
tients with fungal 
infections 
c) No significant dif- 
ference between 
groups in alexithy- 
mia ratings. 
Matussek et 
al. [16] 1985 
38 Inpatients and 113 depressives Questionnaire for Psoriatics demon- 
outpatients 32 healthy controls Measuring Factors strated “highest 
of Aggression spontaneous 
(FAF) (Hampel, aggression”, 
1975) “marked aggres- 
sion toward oth- 
ers” and “low 
autoaggression.” 
Ametz et al. 
[17] 1985 
10 Patients who re- 10 healthy subjects Psychological stress During stressor expo- 
ported that their induced by a) sure, psoriatics re- 
psoriasis was color-word conflict ported a) 
aggravated by test and b) forced significantly higher 
psychosocial mental arithmetic levels of stress and 
factors b) excreted more 
urinary adrenalin 
than controls. 
Payne et al. 
[18] 1985 
16 Outpatients with 16 patients with cu- Life Events Inventory No significant differ- 
psoriasis who taneous neo- ]I91 ence in the number 
completed a ret- plasms, warts, of life events dur- 
respective postal fungal infection ing the previous 2 
questionnaire years between 2 
groups 
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chopathology, 3) psychosocial problems associated 
with adaptation to a chronic and cosmetically dis- 
figuring disease, and 4) biochemical and physio- 
logic abnormalities in psoriasis that interface with 
psychiatry. In our experience at the Psychoder- 
matology Clinic, all these four areas must be taken 
into consideration in the psychiatric evaluation and 
management of patients with psoriasis. This article 
also provides the clinician with some practical 
guidelines for the management of some of these 
problems. 
Psychosocial “Stress” and Psoriasis 
There is a relatively large body of literature impli- 
cating stressful life situations in precipitating and/ 
or exacerbating psoriasis [2-7,11,15,17,20,22-271. 
However, the nature of this association remains 
unclear. In a survey of over 4500 dermatologic pa- 
tients, 2% of the patients had psoriasis, and emo- 
tional factors were reported to “trigger the onset 
of symptoms” in 62% of the psoriatics [24]. In a 
Danish study involving 245 children with psoriasis, 
“stress” was observed to be a provocative factor in 
90% of patients [27]. Ingram [23] observed that psy- 
chosocial stressors exerted “the most potent influ- 
ence” on psoriasis, whereas Baughman et al. [ll] 
report that the effect of “stress” was “modest but 
significant.” Both these conclusions are based 
upon uncontrolled observations. The studies using 
controls [5,71 report that psychosocial factors were 
important in the onset and/or exacerbation of 
symptoms in 39% [5] to 80% [7] of psoriatics versus 
10% [5] to 50% [7] of controls, respectively. The 
controls consisted of patients with a range of non- 
dermatologic disorders [5] and patients with fungal 
infections of the skin [7]. On the other hand, based 
upon the results of a postal survey, Payne et al. 
[18] observed no difference in the number of life 
events between psoriatics and other dermatologic 
controls, concluding that “stress” did not play an 
important role in psoriasis. They asked their pa- 
tients to note any events that occurred 12 months 
prior to the onset of psoriasis on a life events check- 
list adapted from the Life Events Inventory [19] 
without ascertaining the degree of “stress” asso- 
ciated with the event. In the studies where a sig- 
nificant relationship has been noted between the 
onset or exacerbation of psoriasis and life events, 
the subjects had been asked whether they had ex- 
perienced “specific stress” 1 month before the on- 
set of psoriasis [5], or whether they had a 
“stressful” life event 6 months prior to the onset 
of psoriasis in a semistructured interview [7]. It 
appears that the important factor is the psychologic 
distress or “stress” experienced by the patient 
rather than the life events per se. This is supported 
by a previous observation that the onset of pso- 
riasis was clearly associated with a stressful life 
event only when the event was of “an acute cat- 
astrophic nature,” for example, sudden death of a 
relative [4]. In such a case it is reasonable to assume 
that most people would experience significant psy- 
chologic distress. Furthermore, in a recent study, 
Ametz et al. [17] have demonstrated that psoriatics 
experienced “significantly higher strain levels” in 
comparison with healthy controls, when both were 
exposed to the same stress provoking situation. 
This was measured by scores on standard ques- 
tionnaires and increased urinary adrenalin levels 
[17]. It is also interesting to note that psoriatics who 
reported “specific stress” 1 month before the onset 
of psoriasis [5] were also observed to have better 
prognosis three years later [28]. It is possible that 
a subgroup of psoriatics who are “stress reactors” 
experience a relatively benign clinical course, as 
their symptoms subside after the stress-provoking 
situation becomes less bothersome or subsides. 
Identification of such patients early in the course 
of treatment and incorporation of specific psycho- 
social interventions in the overall treatment regi- 
men may improve the course of illness. Although 
the concept of “stress” is difficult to operationalize, 
treatments such as supportive psychotherapy and 
facilitation of grieving may prove to be important 
clinical interventions in some patients. It has been 
observed that children with psoriasis “react more 
easily to physical and psychological trauma than 
do adults with psoriasis” [27]. The authors rec- 
ommend that treatment of children with psoriasis 
should involve a close parent-child-physician re- 
lationship and preferably be carried out in an out- 
patient setting to minimize the stress of 
hospitalization [27]. It is possible that in some chil- 
dren with psoriasis who have family pathology, a 
family assessment and family therapy may im- 
prove the course of illness. 
The Association of Psoriasis and 
Psychopathology 
Many investigators have attempted to delineate 
specific personality characteristics in psoriasis us- 
ing questionnaires [4,6,7,10,11,13,16,29,30] and 
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clinical interviews [3]. This is a follow-up on the 
classic work of French and Alexander [31], who 
described neurodermatitis as one of the “holy 
seven” psychosomatic disorders, and the pioneer- 
ing work of psychoanalytically oriented psychia- 
trists like Wittkower [32], who looked for 
relationships between personality structure, emo- 
tional conflict, and skin disease [32]. Although 
most have concluded that psoriatics do not have 
any characteristic personality traits [3,4,6,11,13], 
some have reported high measures of outward 
aggression [16], high depression [7,30], high anx- 
iety [7], and high obsessionality [29] and psych- 
asthenia [lo] scores on various psychologic 
questionaires (Table 1). The clinical relevance of 
these findings is difficult to evaluate, as all the 
studies have involved a one-time cross-sectional 
evaluation of personality characteristics 
[3,4,6,7,10,11,13,16,29,30]. In one study where the 
ages of the patients ranged between 15 and 83 years 
and duration of psoriasis ranged between 5 and 40 
years [lo], the relation between duration of symp- 
toms and personality characteristics was evaluated, 
and no consistent patterns emerged. Although 
some of the abnormal psychologic characteristics 
reported are most likely a reflection of the reaction 
to adaptation to a chronic cosmetically disfiguring 
illness, in some instances onset of psoriasis during 
developmentally critical periods may also affect the 
psychological growth of the individual [33]. To our 
knowledge, evaluations of psychiatric syndromes 
among psoriatics, employing standard diagnostic 
criteria, for example DSM-III, have not been 
reported. 
Chaput et al. [34] have reported a higher prev- 
alence of psoriasis among individuals who con- 
sumed more than 50 g of ethanol per day. Morse 
et al. [9] have recently reported an 18% prevalence 
of alcoholism among psoriatics versus a 2% prev- 
alence among other dermatologic controls, using 
the criteria of the National Council for Alcoholism 
and the Self-Administered Alcohol Screening Test. 
They also found no relationship between alcohol- 
ism and the duration of psoriasis, suggesting per- 
haps that having psoriasis alone predisposes the 
patient to developing alcoholism. Previous reports, 
using less stringent diagnostic criteria for alcohol- 
ism [35-371 have refuted the association between 
alcoholism and psoriasis. Alcoholism among pso- 
riatics may, for example, represent an underlying 
depressive illness, or may represent an attempt at 
self-medication for, e.g., anxiety, social phobias, or 
sleep difficulties. This has important treatment im- 
plications and requires further evaluation. 
Psychosocial Problems Encountered as a 
Result of Psoriasis 
Body Image 
Disfigurement occurring during adolescence has 
been reported to have a great impact on body image 
in later life [38,39]. This may be especially impor- 
tant in psoriasis, where 58% of patients develop 
psoriasis before age 30 years, 35% before age 20 
years, and 10% before age 10 years [40]. Presence 
of lesions on exposed body parts [41] and increased 
severity [42] have both been reported to adversely 
affect the patient’s body image. 
Sexual Functioning 
Psoriasis has been reported to effect the sexual 
functioning of the patient in 72% of cases [43]. 
When psoriasis is present in the more “emotionally 
charged’ areas of the body, such as the genital 
area, sexual functioning is more affected [44]. 
Trauma to the genitals following sexual activity can 
result in new psoriatic lesions or an exacerbation 
of previous lesions as a result of the Koebner phe- 
nomenon, a feature of psoriasis where new pso- 
riatic lesions have a tendency to appear at sites of 
trauma [45]. The fear of passing on psoriasis to the 
offspring, and myths about the possibility of con- 
tagion may also lead to significant sexual problems 
[3]. Marriage may be deferred [32,33] as a result of 
these concerns. 
Others 
Psoriasis has been associated with contagion, filth, 
and leprosy for centuries [43,44]. Wittkower and 
Russell [32] observed that psoriasis was often at- 
tributed to “venereal disease, dirt, and neglect,” 
leading to a “considerable social effect.” Presence 
of psoriasis in areas of high visibility such as face 
and hands can impair social and occupational func- 
tioning to a significant degree [3,32,33,43,44]. The 
patient may be discriminated against in public 
places such as beaches and hotels and in hairdress- 
ing salons. They frequently give up swimming, 
sunbathing, and activities that necessitate expo- 
sure of their skin to others [3,46]. Light-colored 
clothing may be chosen to cover the affected re- 
gions of the skin and camouflage the scales that 
Psoriasis and Psychiatry 
are shed [3,33,46]. Patients may develop a perva- 
sive preoccupation with the anticipated negative 
response of others and, while dealing with these 
day-to-day problems, may experience a sense of 
“losing control” when faced with an unexpected 
exacerbation of their illness [33]. A poignant de- 
scription of this has been given by Updike [47,48]. 
Medical treatments for psoriasis in day care cen- 
ters versus inpatient hospitalization, for example, 
may interfere less with the daily functioning of the 
patient [49]. Education of the public, regulations 
ensuring that patients with psoriasis are not dis- 
criminated against in public facilities such as 
beaches and hotels [49,50], and group therapy 
aimed at dealing with the personal and social prob- 
lems associated with psoriasis [33,51,52] are all im- 
portant. The preliminary results of a recent large 
scale self-report survey, carried out by the National 
Psoriasis Foundation (531 reports that psoriasis did 
not significantly interfere with patients’ social re- 
lationships. It is possible that this reflects an in- 
creasing awareness among the general population 
about the myth regarding psoriasis. 
Physiological and Biochemical 
Correlates of Psoriasis that Interface 
with Psychiatry 
Lithium and Psoriasis 
Lithium may precipitate and frequently exacerbate 
psoriasis [54,55]. This effect is believed to be me- 
diated by the effect of lithium on the two intra- 
cellular “second messenger” systems, cyclic 
adenosine monophosphate (CAMP) and the 
phosphoinositides. 
Lithium has an inhibitory effect on adenylate 
cyclase, leading to decreased levels of CAMP 
[56,57]. Psoriasis has been associated with de- 
creased responsiveness of the P-adrenergic recep- 
tors in the epidermal cells [58]. These P-adrenergic 
receptors are linked with the adenylate cyclase- 
CAMP system. Further inhibition of adenylate cy- 
clase by lithium therefore can exacerbate psoriasis. 
Lithium also effects the phosphoinositide pathway 
by inhibiting the enzyme inositol monophospha- 
tase, thus slowing the rate of resynthesis of phos- 
phatidylinositol [59]. In psoriasis abnormalities 
have been found in the arachidonic acid transfor- 
mation cascade [60]. This can be further exacer- 
bated by the effect of lithium on the 
phosphoinositide pathway. An in-depth discus- 
sion of the biochemical abnormalities in psoriasis 
is not within the scope of this article. 
Major depressive disorder has been associated 
with reduction in lymphocytes P-adrenergic re- 
sponsiveness, as measured by agonist-induced 
CAMP production [61]. The lymphocytes have been 
implicated as peripheral models of central p-ad- 
renergic receptor function. This possible defect in 
P-adrenergic receptor function in both psoriasis 
and depressive illness, along with some reports of 
a possibly increased prevalence of depressive 
symptoms [7,33] and alcoholism [9,34] among pso- 
riatics, suggests that the association between pso- 
riasis and affective disorders requires further 
investigation. 
Neuropeptides and Psoriasis 
Farber et al. [62] have proposed that substance I’, 
a neuropeptide involved in itch and pain percep- 
tion and the modulation of inflammation, may be 
involved in psoriasis, especially in cases where the 
lesions follow a symmetric dermatomal distibu- 
tion. Substance I’ has been demonstrated in in- 
traepidermal nerve endings and there have been 
reports of resolution of psoriasis with cutaneous 
nerve resection [63]. The authors further discuss 
that since the epidermis and the nervous system 
are developmentally both derived from the em- 
bryologic ectoderm, neural factors may affect epi- 
dermal cells [62]. 
Cutaneous Blood Flow 
Psoriasis has been associated with increased cu- 
taneous blood flow [64-661, and improvement in 
psoriasis has been associated with a decrease in the 
cutaneous blood flow [66-681. This may be due to 
the change in morphology of the capillaries of pso- 
riatic skin [64]. More than three decades ago Gra- 
ham [69] had observed that cutaneous blood flow, 
as measured by skin temperature and the reactive 
hyperemia threshold, increased significantly in the 
patient with psoriasis when the topic of discussion 
involved a disturbing life situation. In accordance 
with the most popular theories then in vogue, this 
was attributed to an “attitude” that these patients 
might have had in common [69]. 
Several studies [70,71] have reported that tem- 
perature biofeedback training was associated with 
a significant decrease in the severity of psoriasis. 
The efficacy of this method appears to be related 
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to the more generalized relaxation response initi- 
ated by the biofeedback [70,71], rather than de- 
creased cutaneous blood flow. The role of 
psychophysiologic factors affecting cutaneous 
blood flow, in the exacerbation of psoriasis requires 
further evaluation. 
Some Practical Guidelines for 
Psychosocial Intervention in Psoriasis 
The psychiatrist is typically called upon a) to man- 
age psychiatric pathology such as affective disorder 
in the psoriatic patient and b) for a psychophar- 
macologic consultation, when psoriasis is precipi- 
tated or exacerbated in a patient being maintained 
on lithium. 
The patient must be evaluated within a devel- 
opmental context, and the social, occupational, and 
close interpersonal functioning of the patient must 
be assessed, along with the psychiatric pathology 
including suicide risk. The assessment of the day- 
to-day difficulties faced by the patient is especially 
important, as in the subgroup of “stress reactors” 
having to cope with this may alone exacerbate the 
skin condition. Psychologic interventions aimed at 
helping the patient deal with these “stresses” may 
be helpful. Several studies report the efficacy of 
hypnosis-induced relaxation [72-741 and psycho- 
therapy [75,76] as a helpful adjunct in the treatment 
of psoriasis. In our experience, brief hospitalization 
aimed at removing the patient from a stressful en- 
vironment may lead to significant improvement of 
psoriasis in some cases. 
Potent topical steroids frequently used to treat 
psoriasis may be systemically absorbed and alter 
the mental state of the patient [30], and may de- 
press adrenocortical function [77], thus affecting 
diagnostic procedures such as the dexamethasone 
suppression test. 
Psoriasis precipitated or exacerbated by lithium 
is typically fairly resistant to conventional anti- 
psoriatic treatment [78]. This may occur within the 
first few months of treatment and usually occurs 
within the first few years that the patient is on 
lithium [79,80] Usually there is no family history 
of psoriasis [78]. When the psoriasis becomes wide- 
spread and intractible, lithium has to be discontin- 
ued [79] and the psoriasiform rash usually remits 
within a few months [78], or the rash reverts back 
to its premorbid state [78]. Having to discontinue 
lithium can typically pose a major management 
problem for the psychiatrist. For the bipolar patient 
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discontinuing lithium, alternative treatments such 
as carbamazepine may be necessary, and the pa- 
tient may need antipsychotic or antidepressant 
medications for stabilization of the mood disorder. 
The phenothiazine antipsychotics [81,82] and some 
antidepressants [83-851 can cause a photosensitive 
skin rash when a patient is exposed to ultraviolet 
A (WA) light. Since WA with psoralens (PWA) 
is frequently used as a treatment for psoriasis, this 
side effect may also interfere with the management 
of psoriasis. Management of patients whose mood 
disorder does not stabilize without lithium involves 
an ongoing evaluation of the risk-to-benefit ratio 
associated with reintroduction of lithium. In some 
cases, lithium may have to be restarted for a limited 
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